17
Oct
2017
VC Briefs: Gemini’s $42M for Dry AMD & Mission Bio’s $10M for Single-Cell Analysis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2017
Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Oct
2017
Spark Gene Therapy Sails Thru AdComm, Broad Institute Nuzzles Up to Deerfield, Pfizer’s Cancer Deal in Africa
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Oct
2017
George Yancopoulos on Threading the Price Needle, and Building a Biotech to Last
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2017
Where Does Alzheimer’s R&D Go Now? Plenty of Directions
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2017
IPO Market Finds a Rhythm, FDA Huddles with FTC on Pricing, & Praluent Gets to Stay
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Oct
2017
Nimbus Rinses and Repeats, Enticing Celgene With Immunology Drug Candidates
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2017
KSQ Scores $76M, Lures Meeker to CRISPR Dream of ‘High Confidence Drug Development’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Sep
2017
The Long Run Ep. 2: Editas Medicine CEO Katrine Bosley
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Sep
2017
Socializing After Hours: It’s How Biotech Runs, and Should Be Open to All
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Sep
2017
Alnylam Gets Over the Hump, Nabriva Nails Antibiotic Trial & Biosimilar Avastin Arrives
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Sep
2017
After the Boom: How’s It Going for Big Pharma Vets At Startups?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Sep
2017
The Long Run, Ep. 1: Conversation with Alnylam CEO John Maraganore
Podcast listeners, check it out: Today, I’m starting a new podcast for biotech adventurers like you – executives, investors, scientists. It’s called The Long Run. Here’s the gist: Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return... Read More
11
Sep
2017
Corporate VCs: How Do They Get Rewarded? How Should They Be Rewarded?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2017
Allergan’s Tribal Patent Switcheroo; Cellectis, Alnylam See Trial Deaths; & Execs Defend Dreamers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2017
Replimune, Led by BioVex Vets, Snags $55M for New Oncolytic Viruses for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2017
Gritstone Grabs $93M, Doubling Down on Personalized Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Sep
2017
Novartis’ Historic CAR-T Approval, Gilead-Kite Megadeal, & FDA Crackdown on Stem Cell Hucksters
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Aug
2017
How Gilead Can Play to Win in CAR-T Over the Next Decade
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Aug
2017
Getting to Precision Medicine – It’s Complicated
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.